<DOC>
	<DOCNO>NCT01645215</DOCNO>
	<brief_summary>Fruquintinib ( HMPL-013 ) novel oral small molecule selectively inhibit vascular endothelial growth factor receptor ( VEGFR ) 1 , 2 , 3 demonstrate potent inhibitory effect multiple human tumor xenograft . This first-in-human study conduct assess maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) , evaluate pharmacokinetics , safety preliminary anti-tumor activity HMPL-013 single dos multiple dos .</brief_summary>
	<brief_title>Phase I Study Fruquintinib ( HMPL-013 ) Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This open-label , phase I study . This study evaluate safety pharmacokinetics HMPL-013 single administration follow 28-Day continuous course therapy ; evaluate safety preliminary efficacy open-label administration MTD . All subject study permit continue therapy safety monitoring bimonthly assessment progression , product well tolerated subject stable disease well .</detailed_description>
	<criteria>≥ 18 ≤ 70 year age Histological cytological confirm solid malignant tumor ECOG performance status 01 Standard regimen fail standard regimen available Life expectancy 12 week LVEF ≥ 50 % Duration last therapy 4 week operation radiotherapy ; 4 week prior systemic treatment Adequate hepatic , renal , heart , hematologic function ( platelet &gt; 80 × 109/L , neutrophil &gt; 1.5 × 109/L , hemoglobin &gt; 90g/dl , serum creatinine within upper limit normal ( ULN ) , total bilirubin serum transaminase within upper limit normal ( ULN ) , PT , APTT , TT , Fbg normal At least one measurable lesion ( large 10 mm diameter spiral CT scan ) sign date informed consent.Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure Pregnant lactate woman Any factor influence usage oral administration Evidence uncontrolled CNS metastasis Intercurrence one following : noncontrolled hypertension , coronary artery disease , arrhythmia heart failure Abuse alcohol drug Less 4 week last clinical trial Previous treatment VEGF/VEGFR inhibition Disability serious uncontrolled intercurrence infection Proteinuria ≥ 2+ Uncontrolled hemorrhage GI Within 12 month first treatment occur artery/venous thromboembolic event , cerebral vascular accident ( include transient ischemic attack ) etc . Within 6 month first treatment occur acute myocardial infarction , acute coronary syndrome CABG Bone fracture wound cure long time Coagulation dysfunction , hemorrhagic tendency receive anticoagulant therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>